- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01899196
Epicardial Adipose Tissue And Coronary Risk In HIV-Infected Patients (ANRS EP 52)
EPICARDIAL ADIPOSE TISSUE AND CORONARY RISK IN HIV-INFECTED PATIENTS
Protocol date and version RCB Id : 2013-A00547-38
Etude ANRS EP 52 PIECVIH Title of Study: EPICARDIAL ADIPOSE TISSUE AND CORONARY RISK IN HIV-INFECTED PATIENTS
Short title - PIECVIH study
Sponsor French National Institute for Health and Medical Research - French national agency for research on AIDS and viral hepatitis (Inserm-ANRS)
Coordinating Investigator Pr Franck BOCCARA Service de Cardiologie, Hôpital St Antoine INSERM UMRS 938 Paris, UPMC, Institut hospitalo-Universitaire- Institute of Cardiometabolism and Nutrition (IHU-ICAN) 184, rue du Faubourg Saint-Antoine 75571 PARIS Cedex 12 Tél. : 01 49 28 24 49 - Fax : 01 49 28 26 83 Courriel : franck.boccara@sat.aphp.fr
Participating country: France
Objectives Principal objective To compare the inflammatory profile of the epicardial adipose tissue (EAT) between people living with and without HIVwho present with coronary heart disease and will undergo a coronary artery bypass graft (CABG)
Secondary objectives
- To compare the volume of EAT between people living with and without HIV who present with coronary heart disease
- To evaluate the relationship between the abnormalities of the expression profiles of the adipocytokines and cytokines with the atherosclerotic lesions.
- To evaluate the relationship between the abnormalities of the expression profiles of the adipocytokines and cytokines of the EAT with the circulating levels and metabolic parameters.
- To compare the histological and inflammatory profiles of the EAT with the subcutaneous adipose tissue for each patient individually.
Methodology multicentric, comparative study
Estimated enrollment 31 participants in total
- st group of- 15 people living with HIV undergoing CABG (coronary heart disease HIV+ group)
- nd group of- 16 people without HIV- undergoing CABG (coronary heart disease HIV- group) People without HIV-will be matched to people living with HIV+ by : age (± 5 years) and sex Outcomes
Primary outcome:
Comparative analysis of the inflammatory profile of the EAT : expression profile of the pro and anti inflammatory cytokines and adipokines within the EAT in both groups of participants : coronary heart disease HIV+ and HIV- groups
Secondary outcomes :
- Determination of the EAT volume by echocardiography and cardiac scanner for both groups
- Macroscopic profile of the EAT : adipocytes, fibrosis, endothelial cell density)
- RT-PCR analyses : renin, adiponectine, PPARɣ
- Comparatison of the inflammatory and macroscopic profiles between the EAT and the subcutaneous adipose tissue in the two groups by ARN messagers analysis.
Eligibility Inclusion criteria HIV+ group
- Men or women above the age of 18 years old, HIV1 seropositive for more than 6 months
- Individual undergoing, for the first time, cardiac surgery for CABG
- Affiliated with a social security regimen (the AME is not a social security regimen)
- Signed the consent form
HIV- group
- Men or women above the age of 18 years old, HIV seronegative
- Individuals undergoing, for the first time, cardiac surgery for CABG
- Affiliated with a social security regimen (the AME is not a social security regimen)
- Signed the consent form
Non-inclusion criteria History of surgery for CBAG and/or congenital heart defect- being under the tutorship or guardianship of the state or in custody of the justice system.
Statistical methods Categorical variables will be compared using Fisher's exact test. Continuous variables will be compared using the Student's t-test (parametric) and the Wilcoxon-Mann-Whitney test (non-parametric) as appropriate considering the data distribution. (statistical analysis software STATA 11 (StataCorp, Texas, USA))
Provisional study planning and timetable Study start date: July 2013 Enrollment period: 32 months Subject participation duration: 24 hours Total study duration: 32 months Estimated study completion date: end of March 2016
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75012
- Hospital St Antoine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
VIH + GROUP:
- Men or women > 18 years old, HIV1 + for more than 6 months
- Planned first cardiac surgery for CABG
VIH - GROUP:
- Men or women > 18 years old,
- Planned first cardiac surgery for CABG
Exclusion Criteria:
- History of cardiac surgery
Study Plan
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: no Arm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
comparison of the inflammatory profile of the epicardial adipose (EAT) tissue between HIV-infected and uninfected patients undergoing cardiac surgery for coronary artery bypass graft (CABG)
Time Frame: day 1
|
day 1
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
comparison the volume of EAT between HIV-infected and uninfected patients undergoing cardiac surgery
Time Frame: day 1
|
day 1
|
|
Evaluation of the relations between the adipocytokines and cytokines profile in the EAT and in the systemic circulation.
Time Frame: day 1
|
day 1
|
|
Comparison of the histological and inflammatory profiles of the EAT and the subcutaneous adipose tissue of each patients.
Time Frame: day 1
|
day 1
|
|
Evaluation of the relations between the adipocytokines and cytokines profile in the EAT and coronary artery lesions.
Time Frame: day 1
|
day 1
|
Collaborators and Investigators
Investigators
- Principal Investigator: Pascal LEPRINCE, Hôpital La Pitié Salpétrière Paris
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ANRS EP 52 PIECVIH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hiv Infection
-
Federal University of São PauloGilead SciencesCompleted
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Fundación HuéspedViiV HealthcareNot yet recruitingHIV-1-infectionArgentina, Brazil
-
Fundación HuéspedMSD Pharmaceuticals LLC; Fundacion IDEAANot yet recruiting
-
Henan Genuine Biotech Co., Ltd.Recruiting
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruiting
-
BioNTech SERecruitingHIV -1 InfectionGermany, United States
-
TaiMed Biologics Inc.Active, not recruitingHIV -1 InfectionUnited States
-
University of North Carolina, Chapel HillNot yet recruiting
-
Craig Cohen, MD, MPHNational Institute of Allergy and Infectious Diseases (NIAID); Duke University and other collaboratorsRecruiting
Clinical Trials on blood sampling,
-
Institut du Cancer de Montpellier - Val d'AurelleRecruitingGlioma | Sarcoma | Cancer | Breast Cancer | Colon Cancer | Lung CancersFrance
-
Medical University of GrazJoanneum Research Forschungsgesellschaft mbHCompleted
-
CardioRenalCompletedPotassium MeasurementBelgium
-
Fondazione Policlinico Universitario Agostino Gemelli...Active, not recruiting
-
Centre Hospitalier Universitaire DijonCompletedPatients With Intellectual Disabilities Without an Obvious Clinical Diagnosis | Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)France
-
Assistance Publique - Hôpitaux de ParisURC Necker Cochin, FranceCompletedSepsis | Acute Circulatory FailureFrance
-
Royal Surrey County Hospital NHS Foundation TrustCompletedThyroid Carcinoma | Thyroid Cancer | Cancer of the Thyroid | Cancer of ThyroidUnited Kingdom
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Rennes University HospitalCompletedMultiple SclerosisFrance
-
Institut PasteurSanofi Pasteur, a Sanofi Company; Institut Pasteur of Cote d'IvoireCompletedBordetella Pertussis, Whooping CoughCôte D'Ivoire